Company Overview and News

 
TMX Group signs agreement with Shanghai Clearing House

2018-10-11 reuters
Oct 11 (Reuters) - Canada’s biggest stock exchange operator TMX Group Ltd said on Thursday it signed an agreement with the Shanghai Clearing House (SHCH) as it looks to expand its footprint in China’s financial markets.
X TMXXF

 
Avante Logixx to add Chief People and Legal Affairs Officer

2018-09-21 globenewswire
TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Avante Logixx Inc. (TSXV: XX) (“Avante” or the “Company”) is pleased to announce that Scott Goodman will join Avante as the Company’s Chief People and Legal Affairs Officer effective October 2, 2018. Scott previously held roles at the TMX Group Inc. and Parmalat Canada. He is a people operations leader and lawyer with success across multiple industries designing and implementing effective people systems.
X TMXXF ALXXF XX

 
TMX Group's (TMXXF) CEO Lou Eccleston on Q2 2018 Results - Earnings Call Transcript

2018-08-12 seekingalpha
Good morning. My name is Leandra, and I will be your conference operator today. At this time, I would like to welcome everyone to the TMX Group Second Quarter 2018 Results Conference Call. [Operator Instructions]. Thank you, Mr. Paul Malcolmson, you may begin your conference.
X TMXXF

 
TMX posts higher quarterly profit on asset sale

2018-08-09 reuters
(Reuters) - Canada’s biggest stock exchange operator TMX Group (X.TO) reported a nearly 44 percent increase in quarterly profit on Wednesday, helped by a C$26.8 million gain on the sale of its interest in FTSE TMX Global Debt Capital Markets Ltd.
X TMXXF

 
UPDATE 1-Canada's TMX says no plans for talks with Saudi Aramco over IPO

2018-08-08 reuters
Aug 8 (Reuters) - Canada’s TMX Group Ltd said on Wednesday it had no plans for further talks with oil company Saudi Aramco about a partial listing on the Toronto Stock Exchange as part of what is expected to the world’s largest initial public offering.
X TMXXF

 
Canada's TMX says no plans for talks with Saudi Aramco over IPO

2018-08-08 reuters
Aug 8 (Reuters) - Canada’s TMX Group Ltd said on Wednesday it has not had recent talks with Saudi Aramco about a partial listing on the Toronto Stock Exchange as part of the oil firm’s initial public offering, and that it currently has no plans for further dialogue.
X TMXXF

 
RPT-Canada's TMX says no plans for talks with Saudi Aramco over IPO

2018-08-08 reuters
Aug 8 (Reuters) - Canada’s TMX Group Ltd said on Wednesday it has not had recent talks with Saudi Aramco about a partial listing on the Toronto Stock Exchange as part of the oil firm’s initial public offering, and that it currently has no plans for further dialogue.
X TMXXF

 
Canada’s Pot Exchange Publishes Investors’ Personal Information - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
X TMXXF CHMJF

2
Swiss Stock Exchange Plans Platform for Cryptocurrencies Like Bitcoin | Fortune

2018-07-06 fortune
The Swiss stock exchange is going to open a cryptocurrency exchange, which it claims will be the first of its kind in the world.
X TMXXF DTK ICE

18
QuoteMedia to Present at the 8th Annual LD Micro Invitational

2018-05-29 accesswire
LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data, cloud-based financial web content solutions and stock market applications, will be presenting at the 8th annual LD Micro Invitational on Tuesday, June 5 at 5:00 PM PST. Dave Shworan will be presenting and meeting with existing and potential clients and investors of QuoteMedia.
GEC GE X TMXXF DOW GNE THFF

18
QuoteMedia Provides QMod Market Data Solutions to Equisolve for IR Website Offering

2018-05-16 globenewswire
PHOENIX, May 16, 2018 (GLOBE NEWSWIRE) -- QuoteMedia, Inc. (OTCQB:QMCI) today announced an agreement to provide market data feed services and financial applications to Equisolve.
GEC GE X TMXXF DOW GNE THFF

3
CANADA STOCKS-TSX futures rise on strong commodity prices

2018-05-11 reuters
May 11 (Reuters) - Canada’s main stock index futures edged higher on Friday, helped by strong commodity prices on the back of a weaker U.S. dollar.
X TMXXF

3
Bank of Canada, TMX say blockchain feasible for securities settlement

2018-05-11 reuters
TORONTO, May 11 (Reuters) - Canada’s central bank, Toronto Stock Exchange operator TMX Group, and non-profit organization Payments Canada said on Friday that tests had shown blockchain technology can be used for automating instantaneous securities settlements.
X TMXXF

3
UPDATE 1-TMX CEO says it is still in the running for Saudi Aramco listing

2018-05-10 reuters
TORONTO, May 10 (Reuters) - Canada’s TMX Group Ltd is still in discussions with Saudi Aramco to get the oil company to list on the Toronto Stock Exchange (TSX) as part of its highly anticipated initial public offering, expected to be the biggest IPO in history, TMX CEO Lou Eccleston said on Thursday.
X TMXXF

11
CANADA STOCKS-TSX climbs on gold miners, Enbridge Inc

2018-05-10 reuters
TORONTO, May 10 (Reuters) - Canada’s main index climbed higher on Thursday, as gold miners gained along higher with prices for the precious metal, and Enbridge Inc was boosted by strong results.
ENBBF TMXXF OTEX TXCX ENB GCGMF ENB GC X OTC MGA MG EBBNF ATHOF ATH TU

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...